Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study

[1]  C. Beckmann,et al.  Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects , 2011, BMC complementary and alternative medicine.

[2]  T. Aiko,et al.  New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points , 2011, Gastric Cancer.

[3]  M. Kröz,et al.  Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[4]  A. Zwinderman,et al.  I’m so tired: biological and genetic mechanisms of cancer-related fatigue , 2010, Quality of Life Research.

[5]  H. Kiene,et al.  Review Article: Influence of Viscum album L (European Mistletoe) Extracts on Quality of Life in Cancer Patients: A Systematic Review of Controlled Clinical Studies , 2010, Integrative cancer therapies.

[6]  Michael Adler,et al.  Pharmacokinetics of natural mistletoe lectins after subcutaneous injection , 2010, European Journal of Clinical Pharmacology.

[7]  D. Sargent,et al.  Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. , 2010, JAMA.

[8]  K. Linde,et al.  Mistletoe therapy in oncology. , 2008, The Cochrane database of systematic reviews.

[9]  J. Ji,et al.  Neoadjuvant chemotherapy versus none for resectable gastric cancer. , 2007, Cochrane Database of Systematic Reviews.

[10]  R. Gibson,et al.  Mucosal injury from targeted anti-cancer therapy , 2007, Supportive Care in Cancer.

[11]  G. Bovo,et al.  Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients. , 2006, Hepato-gastroenterology.

[12]  H. Selbmann,et al.  Zusammenhang der NK-Zellaktivität gegen autologe Tumor- und K562-Zellen mit dem klinischen Verlauf unter Misteltherapie , 2006, Complementary Medicine Research.

[13]  W. Hatzmann,et al.  Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. , 2005, Anticancer research.

[14]  R. Lüdtke,et al.  Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects. , 2005, European journal of medical research.

[15]  T. Hickish,et al.  Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. , 2005, European journal of cancer.

[16]  H. Fiebig,et al.  Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. , 2005, Anticancer research.

[17]  John R. Mackey,et al.  Gastric Adenocarcinoma: Review and Considerations for Future Directions , 2005, Annals of surgery.

[18]  G. Bovo,et al.  Biological, histological, and clinical impact of preoperative IL‐2 administration in radically operable gastric cancer patients , 2004, Journal of surgical oncology.

[19]  M. Rostock,et al.  Randomized and Double-Blind Studies – Demands and Reality as Demonstrated by Two Examples of Mistletoe Research , 2004, Complementary Medicine Research.

[20]  G. Di Stefano,et al.  Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. , 2004, Journal of experimental & clinical cancer research : CR.

[21]  Hai-rim Shin,et al.  2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. , 2004, Cancer research and treatment : official journal of Korean Cancer Association.

[22]  H. Stauder,et al.  Mistletoe Extracts Standardised in terms of Mistletoe Lectins (ML I) in Oncology: Current State of Clinical Research , 2002, Oncology Research and Treatment.

[23]  U. Mengs,et al.  Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. , 2002, Anticancer research.

[24]  E. León-Rodríguez,et al.  Adenocarcinoma of the Stomach: Univariate and Multivariate Analysis of Factors Associated With Survival , 2002, American journal of clinical oncology.

[25]  T. Sano,et al.  The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? , 2001, Critical reviews in oncology/hematology.

[26]  E. Tokunaga,et al.  Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis , 2001, American Journal of Gastroenterology.

[27]  T. Kajiwara,et al.  Suppression of cellular immunity by surgical stress. , 2000, Surgery.

[28]  A. Büssing,et al.  [Development of lymphocyte subsets in tumor patients after subcutaneous administration of mistletoe extracts]. , 1999, Forschende Komplementarmedizin.

[29]  A. Büssing,et al.  Entwicklung lymphozytärer Subpopulationen bei Tumorpatienten nach subkutaner Applikation von Mistelextrakten , 1999 .

[30]  I. H. Engels,et al.  Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. , 1999, Cancer research.

[31]  S. Hong,et al.  Peripheral blood lymphocyte subsets in patients with stomach cancer. , 1995, Journal of Korean medical science.

[32]  Wang Hy,et al.  Neoadjuvant chemotherapy versus none for resectable gastric cancer (Review) , 2007 .

[33]  H. Selbmann,et al.  [Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts]. , 2006, Forschende Komplementarmedizin.

[34]  C. Walko,et al.  Capecitabine: a review. , 2005, Clinical therapeutics.

[35]  V. Bocci.  Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. , 1993, Journal of biological regulators and homeostatic agents.

[36]  S. Chiplunkar.  Immune system and cancer. , 1988, Princess Takamatsu symposia.